André König

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Prognostic Factors

Radiation Induced

Top Venues

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Matthew J Ferris, Hisham Mehanna, Jonathan D Schoenfeld, Makato Tahara, Sue S Yom, Robert I Haddad, André König, Pauline Witzler, Marcis Bajars, Christophe Le Tourneau
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design. Future oncology (London, England) 20 (12) (2024)
Matthew J Ferris, Hisham Mehanna, Jonathan D Schoenfeld, Makato Tahara, Sue S Yom, Robert I Haddad, André König, Pauline Witzler, Marcis Bajars, Christophe Le Tourneau
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design. Future oncology (London, England) 20 (12) (2024)
Matthew J Ferris, Hisham Mehanna, Jonathan D Schoenfeld, Makato Tahara, Sue S Yom, Robert I Haddad, André König, Pauline Witzler, Marcis Bajars, Christophe Le Tourneau
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design. Future oncology (London, England) (2024)
Matthew J Ferris, Hisham Mehanna, Jonathan D Schoenfeld, Makato Tahara, Sue S Yom, Robert I Haddad, André König, Pauline Witzler, Marcis Bajars, Christophe Le Tourneau
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design. Future oncology (London, England) 20 (12) (2024)
Matthew J Ferris, Hisham Mehanna, Jonathan D Schoenfeld, Makato Tahara, Sue S Yom, Robert I Haddad, André König, Pauline Witzler, Marcis Bajars, Christophe Le Tourneau
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design. Future oncology (London, England) (2024)